• 1. Fe3O4@SiO2 core–shell nanoparticles for biomedical purposes: adverse effects on blood cells?
  C. Achilli,G. F. Guidetti,A. Ciana,D. Capsoni,G. Minetti Biomater. Sci., 2016,4, 1417-1421
• 2. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 3. Distinguishing between polymorphic forms of linezolid by solid-phase electronic and vibrational circular dichroism?
  Jadwiga Frelek,Marcin Górecki,Marta ?aszcz,Agata Suszczyńska,Elemér Vass,Wojciech J. Szczepek Chem. Commun., 2012,48, 5295-5297
• 4. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylhydrazines
• Solvents and Organic Chemicals Organic Compounds Heterocyclic Compounds
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Professional Introduction to Compound with CAS No. 212248-62-9 and Product Name: 1-(4-Hydrazinylbenzyl)-1H-1,2,4-triazole

The compound with the CAS number 212248-62-9 and the product name 1-(4-Hydrazinylbenzyl)-1H-1,2,4-triazole represents a significant advancement in the field of chemical and pharmaceutical research. This heterocyclic compound has garnered considerable attention due to its unique structural properties and potential applications in medicinal chemistry. The presence of a triazole ring fused with a benzyl group substituted by a hydrazinyl moiety makes it a versatile scaffold for drug design and development.

Recent studies have highlighted the importance of triazole derivatives in the development of novel therapeutic agents. The 1,2,4-triazole core is known for its stability and ability to form hydrogen bonds, which enhances its binding affinity to biological targets. In particular, the 4-hydrazinylbenzyl substituent introduces reactivity that can be exploited for further functionalization, making it an attractive candidate for synthesizing more complex molecules.

The benzyl group in the compound's structure contributes to its solubility and bioavailability, which are critical factors in pharmaceutical formulations. This feature allows for easier administration and absorption in vivo, potentially improving the efficacy of drugs derived from this compound. Additionally, the hydrazinyl group can participate in various chemical reactions, such as condensation or cyclization, providing a platform for diverse synthetic pathways.

In the realm of medicinal chemistry, the exploration of hydrazine-based compounds has been extensively studied due to their pharmacological properties. The hydrazinyl moiety is particularly interesting because it can interact with biological systems in multiple ways, including enzyme inhibition and receptor binding. This versatility makes it a valuable component in the design of drugs targeting various diseases.

Current research indicates that derivatives of 1-(4-Hydrazinylbenzyl)-1H-1,2,4-triazole show promise in addressing inflammatory and infectious diseases. The triazole ring's ability to modulate immune responses has been observed in several preclinical studies, suggesting its potential as an anti-inflammatory agent. Furthermore, the compound's structure suggests it may have antimicrobial properties, which could be exploited in the fight against drug-resistant pathogens.

The synthesis of this compound involves a multi-step process that requires precise control over reaction conditions to ensure high yield and purity. Advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions, have been employed to construct the triazole ring efficiently. These methods not only enhance the yield but also minimize byproduct formation, ensuring a cleaner reaction profile.

From a computational chemistry perspective, molecular modeling studies have been conducted to understand the interactions between 1-(4-Hydrazinylbenzyl)-1H-1,2,4-triazole and biological targets. These studies have provided insights into how the compound binds to receptors and enzymes at an atomic level. This information is crucial for optimizing drug design and improving therapeutic outcomes.

The pharmacokinetic properties of this compound are also under investigation. Studies have focused on its absorption, distribution, metabolism, and excretion (ADME) profiles to assess its suitability for clinical use. Preliminary data suggest that the compound exhibits favorable pharmacokinetic characteristics, including reasonable bioavailability and moderate metabolic clearance rates.

In conclusion,1-(4-Hydrazinylbenzyl)-1H-1,2,4-triazole (CAS No. 212248-62-9) represents a promising candidate for further development in pharmaceutical applications. Its unique structural features and potential biological activities make it an attractive scaffold for drug discovery efforts. Continued research into this compound will likely uncover new therapeutic opportunities across multiple disease areas.

• 119192-10-8(4-(1H-1,2,4-Triazol-1-ylmethyl)benzenamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)